Cresco Labs Inc. (OTCMKTS:CRLBF) Receives $2.50 Consensus Target Price from Analysts

Cresco Labs Inc. (OTCMKTS:CRLBF) has received a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $2.50.

Several research firms have recently weighed in on CRLBF. Atb Cap Markets cut Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th. Roth Capital upgraded Cresco Labs to a “strong-buy” rating in a report on Sunday, November 10th. Finally, Cormark lowered shares of Cresco Labs from a “moderate buy” rating to a “hold” rating in a research note on Monday, November 11th.

Cresco Labs Trading Up 14.2 %

Shares of CRLBF stock opened at $1.13 on Friday. Cresco Labs has a fifty-two week low of $0.78 and a fifty-two week high of $2.64. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The stock’s fifty day moving average price is $0.95 and its two-hundred day moving average price is $1.36. The company has a market cap of $551.60 million, a PE ratio of -5.65 and a beta of 1.79.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.